ADReCS

Pharmaceutical Information

Drug Name	Nicotine
Drug ID	BADD_D01564
Description	Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.
Indications and Usage	For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.
Marketing Status	approved
ATC Code	N07BA01
DrugBank ID	DB00184
KEGG ID	D03365
MeSH ID	D009538
PubChem ID	89594
TTD Drug ID	D0T8GD
NDC Product Code	17205-601; 58316-010; 11673-195; 11673-879; 37808-900; 37808-948; 43598-447; 59450-003; 59779-443; 70000-0115; 0536-1107; 70677-0030; 52922-001; 58316-009; 75877-0002; 11822-3627; 11822-4975; 21130-820; 37808-533; 37808-658; 43598-448; 49035-195; 55910-313; 66715-9802; 66715-9805; 66715-9806; 70000-0114; 28663-009; 58316-006; 11673-727; 11673-881; 37808-682; 0135-0196; 37808-711; 37808-739; 49035-196; 53329-192; 59450-002; 60429-443; 60429-445; 62011-0351; 63868-734; 70677-0032; 60429-444; 0363-0455; 0363-0457; 66715-9804; 68016-288; 28663-010; 58316-011; 11822-4973; 37808-753; 43598-446; 0009-5401; 50090-1148; 53329-193; 68016-289; 0536-1108; 58316-008; 29485-5271; 50090-2860; 63981-124; 66715-9803; 68196-194; 0536-1106; 61252-3005; 50090-1697; 59450-001; 63981-190; 70677-0031; 0135-0194; 0135-0195; 49035-782; 49348-788; 50090-2837; 59779-445; 62011-0350; 63868-735; 66715-9801; 68016-290; 69842-828; 50392-101; 55742-003; 11673-971; 11822-4974; 37808-707; 37808-849; 50090-6383; 55741-449; 59779-448; 0363-0451; 62011-0349; 81870-001; 11673-269; 11673-424; 21130-269; 43598-445; 53329-191; 69842-605; 70000-0113; 58316-007; 11673-194; 11673-196; 29485-5270; 37808-383; 37808-911; 49035-194; 0009-5400
UNII	6M3C89ZY6R
Synonyms	Nicotine \| Nicotine Bitartrate \| Nicotine Tartrate

Chemical Information

Molecular Formula	C10H14N2
CAS Registry Number	54-11-5; 22083-74-5
SMILES	CN1CCCC1C2=CN=CC=C2
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Cholelithiasis	09.03.01.002	0.000940%		-
Chromaturia	20.02.01.002	0.002131%
Chronic obstructive pulmonary disease	22.03.01.007	0.005516%		-
Cold sweat	08.01.03.024; 23.02.03.002	-	-	-
Completed suicide	08.04.01.010; 19.12.01.001	0.004074%		-
Confusional state	17.02.03.005; 19.13.01.001	-	-
Constipation	07.02.02.001	-	-
Coordination abnormal	17.02.02.004	-	-	-
Coronary artery disease	02.02.01.001; 24.04.04.006	0.000627%		-
Cough	22.02.03.001	0.015295%
Crying	08.01.03.005; 12.02.11.001; 17.02.05.013; 19.04.02.002	0.001379%		-
Cyanosis	02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.007	0.000940%
Cystitis	11.01.14.001; 20.03.02.002	-	-
Delirium	19.13.02.001	-	-
Dental caries	07.09.01.001	0.004137%
Dependence	19.07.06.008	0.003761%		-
Dermatitis	23.03.04.002	-	-	-
Dermatitis bullous	23.03.01.002	-	-
Dermatitis contact	10.01.01.003; 12.03.01.040; 23.03.04.004	0.007773%		-
Diabetes mellitus	05.06.01.001; 14.06.01.001	0.001567%		-
Diarrhoea	07.02.01.001	-	-
Diplopia	06.02.06.002; 17.17.01.005	0.000940%		-
Discomfort	08.01.08.003	-	-	-
Disorientation	17.02.05.015; 19.13.01.002	-	-	-
Disseminated intravascular coagulation	01.01.02.002; 24.01.01.010	0.000940%
Disturbance in attention	17.03.03.001; 19.21.02.002	0.002633%
Dizziness	02.11.04.006; 17.02.05.003; 24.06.02.007	0.017802%
Dizziness postural	02.11.04.008; 17.02.05.004; 24.06.02.008	-	-	-
Drug abuse	19.07.06.010	0.010970%		-
Drug dependence	19.07.06.011	0.046386%		-

The 3th Page First Pre 3 4 5 6 7 Next Last Total 14 Pages